<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415749</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-201-102</org_study_id>
    <secondary_id>HHSO100201600008C</secondary_id>
    <nct_id>NCT04415749</nct_id>
  </id_info>
  <brief_title>NasoShield in Healthy Adults to Study Safety and Immunogenicity</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Immunogenicity of NasoShield Administered as One or Two Doses in Different Dosing Positions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to
      determine if antibodies that protect against anthrax are formed after treatment with
      NasoShield, and to determine whether the formation of these antibodies are affected by
      different positions of administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all healthy volunteers that have
      given written informed consent will undergo screening to determine eligibility for study
      entry. If the healthy volunteer qualifies for the study, they will be randomly assigned to 1
      of 3 treatment groups. Within the treatment group, the participant will be randomized in a
      double-blind manner in a 5:2 ratio to NasoShield or placebo.

      The investigational drug (either NasoShield or placebo) will be administered on Days 1 and 29
      after qualifying into the study. The position of administration and the amount of time the
      subject will need to stay in the specified position will depend on the group to which the
      subject is assigned.

      Participants will return to the investigational site for multiple visits through Day 210
      (approximately 6 months after the second dose). At each visit, the participant will be asked
      about interim medical history and use of any medications, and safety and immunogenicity
      assessments will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 parallel groups defined by dosing position and number of doses</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity to evaluate the safety of NasoShield</measure>
    <time_frame>For 7 days after vaccination</time_frame>
    <description>Subjects will record solicited local and systemic events for 7 days after each dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) to evaluate the safety of NasoShield</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
    <description>All adverse events from Day 1 to Day 57; serious adverse events (SAE), medically attended adverse events (MAAE), and new-onset chronic illnesses (NCI) from Day 1 to Day 210</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-protective antigen (PA) immunoglobulin G (IgG) to evaluate humoral immunogenicity</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
    <description>Titer measured by enzyme-linked immunosorbent assay (ELISA) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxin neutralization antibody 50% neutralization factor (TNA-NF50) titer measured in serum by cytotoxic assay to evaluate humoral immunogenicity</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-protective antigen (PA) immunoglobulin A (IgA) to evaluate mucosal immune response</measure>
    <time_frame>From Day 1 to Day 57</time_frame>
    <description>Titer measured by enzyme-linked immunosorbent assay (ELISA) in serum</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield Two Doses in Position 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and Day 29 in position 2 (Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and Day 29 in position 2 (Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield Two Doses in Position 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and Day 29 in position 3 (Group 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and Day 29 in position 3 (Group 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NasoShield</intervention_name>
    <description>NasoShield is an adenovirus-vectored anthrax vaccine</description>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_label>NasoShield Two Doses in Position 2</arm_group_label>
    <arm_group_label>NasoShield Two Doses in Position 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_label>Placebo in Position 1</arm_group_label>
    <arm_group_label>Placebo in Position 2</arm_group_label>
    <arm_group_label>Placebo in Position 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 18 to 49 years of age, inclusive

          2. Good general health status

          3. Adequate venous access for repeated phlebotomies

          4. Screening laboratory results within institutional normal range or Grade 1 abnormality
             if the Investigator documents clinical insignificance. Creatine kinase or bilirubin
             may be Grade 2 if associated with normal alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) and the Investigator considers the result not to be clinically
             significant due to vigorous exercise or Gilbert's syndrome

          5. Negative drug and alcohol screen at Screening and predose on Day 1

          6. For women who have not been surgically sterilized or who do not have laboratory
             confirmation of postmenopausal status, negative pregnancy test

          7. Willingness to practice a highly effective method of contraception that may include,
             but is not limited to, abstinence, sex only with persons of the same sex, monogamous
             relationship with a postmenopausal partner, monogamous relationship with vasectomized
             partner, vasectomy, surgical sterilization (hysterectomy, bilateral tubal ligation,
             salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD),
             or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28
             days after the last IP dose

          8. Willingness to participate and comply with all aspects of the study through the entire
             study period, including nasopharyngeal swabs and blood and urine samples

          9. Provision of written informed consent

        Exclusion Criteria:

          1. Pregnant, possibly pregnant, or lactating women

          2. Body mass index &gt; 35.0 kg/m2

          3. Positive result for HIV, hepatitis B virus, or hepatitis C virus at Screening

          4. Asthma or other chronic lung disease that is greater than mild in severity.
             Specifically excluded are participants with any of the following events in the past
             year:

               -  Daily symptoms

               -  Daily use of short acting beta 2 agonists

               -  Use of inhaled steroids or theophylline

               -  Use of pulse systemic steroids

               -  Emergency care or hospitalization related to asthma or other chronic lung disease

               -  Systemic steroids for asthma exacerbation

          5. History of diabetes mellitus (gestational diabetes is allowed if treatment was not
             required postpartum and serum glucose is currently in the normal range)

          6. History of coronary artery disease, arrhythmia, or congestive heart failure

          7. Clinically significant ECG abnormality

          8. Poorly controlled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood
             pressure &gt; 95 mmHg) at Screening or predose on Day 1

          9. History of anaphylaxis or angioedema

         10. Known allergy to any of the ingredients in the vaccine formulation

         11. Known allergy or sensitivity to latex

         12. History of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other
             nasal abnormality that might affect vaccine administration

         13. Previous nasal surgery or nasal cauterization

         14. Any symptoms of upper respiratory infection or temperature &gt; 38Â°C within 3 days before
             Day 1

         15. Any symptoms within 24 hours before Day 1 of upper respiratory illness or allergy
             flare-up that, in the opinion of the Investigator, presents as nasal congestion or
             rhinorrhea that could inhibit the proper administration of the IP

         16. Known or suspected malignancy, excluding non-melanoma skin cancers and other early
             stage surgically excised malignancies that the Investigator considers to be
             exceedingly unlikely to recur

         17. Immunocompromised individuals, including those who have used corticosteroids(including
             intranasal steroids), alkylating drugs, antimetabolites, radiation, immune-modulating
             biologics, or other immunomodulating therapies within 90 days before Day 1 or those
             who plan use during the study period

         18. History of autoimmune or demyelinating disease

         19. Use of statin medication within 30 days before Day 1 (see list in Section 6.7.1)

         20. Receipt of intranasal medications (including over-the-counter medications) within 30
             days before Day 1

         21. Receipt of any IP within 30 days before Day 1

         22. Receipt of any vaccine within 30 days before Day 1

         23. Receipt of intranasal vaccine within 90 days before Day 1

         24. Receipt of any licensed or investigational anthrax vaccine in civilian or military
             life

         25. Any change in medication for a chronic medical condition within 30 days before Day 1

         26. Past regular use or current use of intranasal illicit drugs

         27. Any medical, psychiatric, or social condition or occupational or other responsibility
             that in the judgment of the Investigator would interfere with or serve as a
             contraindication to protocol adherence, assessment of safety (including
             reactogenicity), or a subject's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Taylor</last_name>
    <phone>(240) 654-1450</phone>
    <email>jtaylor@altimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Staci Steele</last_name>
    <email>ssteele@altimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Bertoch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Bertoch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anthrax</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

